ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 717,31
0,48%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Altimmune Inc (ALT)

  7. Altimmune Inc (ALT) Actualités

ALT

Altimmune (ALT)

Altimmune Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALT
DateHeureSourceTitreSymboleSociété
25/04/202423h24GlobeNewswire Inc.Altimmune Statement on the Passing of Dr. Stephen HarrisonNASDAQ:ALTAltimmune Inc
27/03/202412h00GlobeNewswire Inc.Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALTAltimmune Inc
27/03/202411h57IH Market NewsU.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early TradingNASDAQ:ALTAltimmune Inc
20/03/202412h30GlobeNewswire Inc.Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024NASDAQ:ALTAltimmune Inc
14/02/202418h04Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALTAltimmune Inc
06/02/202400h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALTAltimmune Inc
26/01/202417h49Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALTAltimmune Inc
02/01/202413h30GlobeNewswire Inc.Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024NASDAQ:ALTAltimmune Inc
08/12/202314h35GlobeNewswire Inc.Water Tower Research US Climate Virtual Investor Conference: Presentations Now Available for Online ViewingNASDAQ:ALTAltimmune Inc
04/12/202314h35GlobeNewswire Inc.Water Tower Research US Climate Investor Conference Agenda Announced for December 7th, 2023NASDAQ:ALTAltimmune Inc
30/11/202322h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALTAltimmune Inc
30/11/202322h24GlobeNewswire Inc.Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of PemvidutideNASDAQ:ALTAltimmune Inc
07/11/202322h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALTAltimmune Inc
07/11/202313h00GlobeNewswire Inc.Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:ALTAltimmune Inc
31/10/202312h30GlobeNewswire Inc.Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023NASDAQ:ALTAltimmune Inc
26/10/202314h15Dow Jones NewsAltimmune Gets FDA Fast-Track Designation for Pemvidutide in NASHNASDAQ:ALTAltimmune Inc
26/10/202313h30GlobeNewswire Inc.Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)NASDAQ:ALTAltimmune Inc
25/10/202313h30GlobeNewswire Inc.Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023NASDAQ:ALTAltimmune Inc
17/10/202313h30GlobeNewswire Inc.Altimmune to Participate at Two Upcoming Investor ConferencesNASDAQ:ALTAltimmune Inc
26/09/202313h30GlobeNewswire Inc.Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of DiabetesNASDAQ:ALTAltimmune Inc
12/09/202313h30GlobeNewswire Inc.Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or OverweightNASDAQ:ALTAltimmune Inc
16/08/202322h14Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ALTAltimmune Inc
16/08/202322h10Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALTAltimmune Inc
10/08/202313h00GlobeNewswire Inc.Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:ALTAltimmune Inc
03/08/202313h30GlobeNewswire Inc.Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023NASDAQ:ALTAltimmune Inc
01/08/202313h30GlobeNewswire Inc.Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)NASDAQ:ALTAltimmune Inc
16/06/202313h30GlobeNewswire Inc.Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023NASDAQ:ALTAltimmune Inc
15/06/202313h30GlobeNewswire Inc.Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023NASDAQ:ALTAltimmune Inc
11/05/202322h07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALTAltimmune Inc
11/05/202313h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALTAltimmune Inc
 Showing the most relevant articles for your search:NASDAQ:ALT

Dernières Valeurs Consultées

EU
BEL20
Bel 20
USI
USTECH100
US Tech 100
EU
MC
Lvmh Moet Hennessy Louis...
EU
BNP
BNP Paribas
EU
PX1
CAC 40
NASDAQ
GOOGL
Alphabet
NASDAQ
AAPL
Apple
NASDAQ
MSFT
Microsoft
EU
CS
Axa
SPI
SP500
S&P 500
EU
GLE
Societe Generale
EU
CAP
Capgemini
FTSE
UKX
FTSE 100
EU
EN
Bouygues
EU
RNO
Renault
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés